Upsher-Smith Laboratories LLC, a United States-based pharmaceutical company, has signed a collaboration agreement with United States-based AmbioPharm Inc to produce and market Corticotropin Injection in the United States, it was reported on Friday.

According to the terms of the contract, Upsher-Smith is submitting the New Drug Application (NDA) for Corticotropin Injection to the United States Food and Drug Administration (FDA) and will market and distribute the product under its own label in the United States, after US FDA approval.

AmbioPharm is to produce the active pharmaceutical ingredient exclusively for Upsher-Smith. A contract manufacturing organisation is to provide Upsher-Smith with the finished product for sale in the United States.

Financial terms of the deal were not revealed.